| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.26 | 4e-14 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.2 | 4e-08 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.14 | 5e-05 |